News & Insights
Latest News
- May 20, 2026 Acuitas Therapeutics Highlights In Vivo CAR T Cell Engineering and Ionizable Lipid Quality Attributes at the 2026 ASGCT Annual Meeting
- April 27, 2026 Acuitas Therapeutics Announces Four Scientific Presentations at the 2026 ASGCT Annual Meeting
- April 13, 2026 Acuitas Therapeutics To Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
Latest Presentations
-
May 25, 2026 Optimization of ALC-315® Yields Superior Ionizable Lipids for LNP Mediated Nucleic Acid Delivery
-
May 15, 2026 Ionizable lipid impurities drive RNA-lipid adduct formation in LNPs, impacting in vivo expression (Presentation)
-
May 12, 2026 Alterations in NHP liver gene expression profiles following intravenous infusion of mRNA-LNP
Page: /
Latest Publications
- May 26, 2026 Cohen et al. (2026) “mRNA delivery of mosaic-8 pan-sarbecovirus RBD vaccines elicits distinct antibody epitope signatures” Cell Reports.
- May 13, 2026 Tálas et al. (2026) “RNA-LNP–mediated in vivo prime editing corrects disease phenotypes in a mouse model of citrullinemia type I” Science Translational Medicine.
- March 4, 2026 Dosey et al. (2026) “Stabilization of the H5 clade 2.3.4.4b hemagglutinin improves vaccine-elicited neutralizing antibody responses in mice” Science Translational Medicine.